# A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

> **NCT05426486** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Caigang Liu** · enrollment: 136 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** ARX788
- **DRUG:** Pyrotinib maleate
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05426486
- **Lead sponsor:** Caigang Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-23
- **Primary completion:** 2025-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05426486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05426486, "A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05426486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*